Its peak sales forecast is of more than $2 billion annually together from the maternal vaccine and an RSV shot for older adults. The case highlights how equitable global access will require better advance planning by drugmakers, governments and health organizations, health officials say. "They could have tried sooner," said Erin Sparrow, WHO's technical officer for the RSV vaccine, referring to Pfizer. Pfizer has yet to take a number of steps needed to make the vaccine available in developing countries, according to global health officials and the company. She still expects it to be several years before the RSV vaccine is launched in lower-income countries.

---